China Urges US to Withdraw Proposed Limits on Outbound Tech Investment

The diplomatic standoff over cross-border capital flows escalated this weekend as Beijing formally demanded the withdrawal of sweeping new American financial regulations. The confrontation centers on a U.S. Treasury directive issued Thursday that subjects billions of dollars in outbound venture capital to strict national security screening.[1][4]

Beijing’s Ministry of Commerce issued a statement Saturday urging Washington to halt the expansion of the Outbound Investment Security Program. The ministry characterized the proposed rules, which add biotechnology and hypersonic systems to restricted sectors, as a discriminatory widening of existing curbs.[1][2]

Chinese officials warned that the expanded framework contradicts the consensus reached by the two nations' presidents during their two meetings over the past six months. The ministry explicitly reserved the right to deploy unspecified countermeasures if the U.S. proceeds with the implementation.[2][3]

"The proposal discriminatorily widened China-related investment restrictions and intensified curbs," the Ministry of Commerce stated in its official release on Saturday. The ministry added that the initiative fundamentally undermines normal international economic cooperation.[2][3]

The diplomatic friction centers on the Comprehensive Outbound Investment National Security (COINS) Act, passed as part of the fiscal year 2026 U.S. defense bill. The legislation codifies and broadens an existing 2023 executive order that initially restricted American funding for Chinese artificial intelligence, quantum computing, and advanced semiconductors.[4][5]

Those initial 2023 restrictions were designed to maintain a targeted approach to technology containment. By restricting only the most advanced nodes of artificial intelligence and quantum computing, the U.S. sought to protect its military edge without entirely decoupling the world's two largest economies.[4]

Under the newly proposed Treasury rules, the geographic scope of the restrictions would also expand significantly. While the original framework focused exclusively on China, Hong Kong, and Macau, the updated regulations designate Russia, Iran, North Korea, and Cuba as additional countries of concern.[4]

Broadening the technology net

The inclusion of biotechnology represents the most consequential shift for cross-border corporate dealmaking. The draft regulations categorize pharmaceutical compounds as a prohibited technology, triggering potential bans on equity investments and joint ventures involving Chinese life sciences firms.[5]

The definition of covered pharmaceutical compounds spans small molecules, vaccines, cell and gene therapies, and recombinant therapeutic proteins. U.S. venture capital firms and pharmaceutical companies would be barred from acquiring equity stakes of 50 percent or more in Chinese entities developing these technologies.[5]

This equity restriction directly targets the corporate models that have gained traction in recent years. Under these structures, American venture capitalists form a new U.S.-based biotechnology company around assets licensed from China, with the Chinese licensor taking a significant equity stake in the new firm.[5]

However, the Treasury Department deliberately carved out exemptions for the traditional asset licensing agreements that dominate the pharmaceutical industry. Western drugmakers will still be permitted to pay cash, milestones, and royalties for the ex-China rights to drugs developed by Chinese laboratories.[5]

The proposed rules mandate that any covered transaction exceeding $50,000 must be reported to the U.S. government, while certain high-risk investments will be prohibited entirely. The framework excludes most passive financial investments, such as standard stock purchases on public exchanges, focusing instead on active capital deployment.[4][5]

U.S. officials maintain that the restrictions are a tailored national security mechanism rather than a broad economic embargo. The Treasury Department stated that the measures are designed to prevent American capital and expertise from accelerating the development of dual-use technologies by foreign adversaries.[3][4]

Compliance and corporate impact

For American investment firms, the expanded rules will require substantially heavier compliance infrastructure. Investors must now conduct a reasonable and diligent inquiry to ensure that their capital does not inadvertently flow into prohibited sectors through foreign subsidiaries or complex corporate structures.[4][5]

The Treasury Department recently demonstrated its willingness to enforce the existing baseline rules, issuing a $200,000 civil penalty to a U.S.-based company. The firm had failed to report a $92,500 investment made by one of its foreign subsidiaries into a private Chinese artificial intelligence developer.[4]

The inclusion of Russia in the updated framework arrives during a period of heightened geopolitical maneuvering. The Treasury's proposal was published just days after the U.S. administration waived certain sanctions on Moscow following a diesel supply agreement, signaling a complex dual-track approach to adversarial economies.[4]

The expansion to hypersonic systems and supercomputing aligns with recent U.S. intelligence assessments regarding the rapid modernization of adversarial militaries. Hypersonic glide vehicles, which can travel at more than five times the speed of sound, are notoriously difficult to track and intercept using conventional missile defense architectures.[4]

Industry analysts note that the outbound investment screening recognizes that financial capital accelerates military capabilities just as effectively as direct technology transfers. The rules aim to close a loophole where U.S. export controls restrict the sale of advanced chips, but U.S. venture capital could previously fund the foreign companies manufacturing them.[4][5]

Next steps for the framework

The Treasury Department has opened the proposed regulations for public comment, with a deadline set for early December 2026. The existing outbound investment rules will remain in active enforcement while the federal government finalizes the expanded scope.[4][5]

Corporate stakeholders are expected to lobby for clearer definitions regarding what constitutes a dual-use biotechnology application. The life sciences sector relies heavily on cross-border collaboration, and companies are seeking assurances that routine research partnerships will not trigger federal scrutiny.[5]

For Beijing, the proposed expansion represents another structural barrier to foreign direct investment at a time when the Chinese economy is navigating domestic headwinds. The Ministry of Commerce's swift and forceful response underscores the strategic importance China places on maintaining access to Western capital markets.[1][2]

The ultimate trajectory of the dispute depends on whether China retaliates with its own restrictions on American firms operating within its borders. Until the final U.S. rules are published, the threat of reciprocal economic measures will continue to hang over bilateral trade relations.[2][3]